Clinical trials: Menopausal Osteoporosis, active
Osteoporosis, Postmenopausal
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
This randomized open label clinical trial will evaluate the effect of continued denosumab alone over 18 months versus denosumab with added abaloparatide for 18 months.
- Trial name
- NCT04467983
- Testing
- Denosumab Injection, Abaloparatide
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
Osteoporosis
Orthorexia Nervosa in Postmenopausal Osteoporosis
A total of 64 female patients diagnosed with osteoporosis based on dual-energy X-ray absorptiometry (DXA) measurements performed within the last six months, and 64 age-matched healthy controls without osteoporosis, will be…
- Trial name
- NCT06947213
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people
- Sponsor
- Beylikduzu State Hospital
Osteoporosis in Post-menopausal Women, Osteoporosis
Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture
The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (HMM910 ) in postmenopausal women with osteoporosis who are at high risk of…
- Trial name
- NCT06949137
- Testing
- Human Umbilical Cord-derived Mesenchymal stem cell
- Where
- China
- Volunteers
- 9 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Osteoperosis
The Investigation of the Effectiveness of Virtual Reality Applications in Postmenopausal Osteoporosis Patients
Osteoporosis is a progressive disease characterised by a decrease in bone mass, deterioration in bone microarchitecture, and increased fragility.
- Trial name
- NCT07231822
- Testing
- Conventional treatment, Virtual reality treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kirsehir Ahi Evran Universitesi
Osteoporosis, Postmenopausal Osteoporosis
Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility.
- Conditions
- Osteoporosis, Postmenopausal Osteoporosis, Frailty, Fragility Fractures
- Trial name
- LUMINOS (NCT07677072)
- Where
- Turkey (Türkiye)
- Volunteers
- 98 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Osteoporosis Risk, Osteoporosis, Postmenopausal
Evaluation of Osteo-Buddy in Improving Osteoporosis Knowledge
This is a pilot randomised controlled trial (RCT) to evaluate the use of a Virtual Health Assistant (VHA) named Osteo-Buddy in improving the knowledge of osteoporosis in older women.
- Trial name
- NCT07034131
- Testing
- Osteo-Buddy, Usual Care
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- SingHealth Polyclinics
Osteoporosis in Post-menopausal Women
Bone Health in Postmenopausal Women: The Effect of Exercise With or Without Medication for Osteoporosis
Osteoporosis is a systemic bone disorder characterised by a reduced bone mass and structural deterioration, increasing the risk of fragility fractures, particularly in women post-menopause.
- Trial name
- BEAT-OP (NCT07267325)
- Testing
- EXERCISE TRAINING, Antiresorptive medication (routine clinical care)
- Where
- United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Menopausal Osteoporosis, Bone Markers
COMPASS - COpenhagen MenoPAuSe Study
During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications.
- Trial name
- COMPASS (NCT07254429)
- Testing
- Triptorelin 11.25 mg, Sodium Chloride 0.9%, Estradiol (E2)
- Where
- Denmark
- Volunteers
- 192 people
- Sponsor
- Martin Blomberg Jensen
Geriatrics Balance Disturbance With High Risk Falling, Osteoporosis, Vestibular Age Related Changes, Female Post-menopausal Based on History
Monitoring Combined Effect of Balance and Strengthening Exercises on Static and Dynamic Balance in Elderly Populations
The purpose of training is to evoke improvements in reactive balance, then the training program may be associated with all postural control systems, including the musculoskeletal system, the cognitive system, as well as the…
- Trial name
- NCT06835413
- Testing
- 1-Balance Exercises A- Standing with a decreased base B- Graded reaching in standing C- Stepping in different directions D- Walking practice 2-Strength and Balance Exercises A- Sit-to-stand B- Heel r
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- South Valley University
Osteopenia, Osteoporosis
Calcium-Rich Food Versus Calcium Carbonate for Bone Health
This study will compare adherence, tolerability, safety, and treatment satisfaction between a calcium-rich food and a traditional calcium carbonate supplement in women ages 40 to 90 who are at increased risk for osteoporosis.
- Conditions
- Osteopenia, Osteoporosis, Bone Health in Perimenopausal Women, Menopause Related Conditions
- Trial name
- NCT07763509
- Testing
- 500 mg calcium from milk-derived minerals, Calcium Carbonate 500 MG
- Where
- United States
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Cornell University
Circadian Rhythm Disorders, Osteoporosis
Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal Osteoporosis
This is a randomized, controlled, and exploratory study designed to evaluate the chronotherapeutic effects of teriparatide administration in postmenopausal osteoporosis.
- Trial name
- NCT06951776
- Testing
- Morning administration group of teriparatide, Evening administration group of teriparatide
- Volunteers
- 28 people
- Sponsor
- Peking University Third Hospital
Osteoporosis, Postmenopausal, Osteoporotic Fractures
Evaluation of a Decision Analysis Model in the DASH-Osteo Decision Aid.
Fragility fractures, often caused by low bone mineral density, are a major health concern for postmenopausal women. One way to prevent these fractures is by taking medication, but deciding whether to start treatment can be…
- Conditions
- Osteoporosis, Postmenopausal, Osteoporotic Fractures, Diphosphonates, Fracture Risk Assessment
- Trial name
- DASH-Osteo (NCT07120854)
- Testing
- Decision aid with decision analysis model, Decision aid alone, Usual Care
- Where
- Spain
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Osteoporosis, Postmenopausal
Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis
This study aims to follow a cohort of osteoporotic patients treated with anti-osteoporotic drugs and to evaluate the impact of these treatments on the osteoporosis-cardiovascular-sarcopenia triad and on pain.
- Trial name
- VASCO (NCT05228262)
- Testing
- Cohort follow-up
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Clermont-Ferrand
Osteoporosis, Osteoporosis, Postmenopausal
Romosozumab Use to Build Skeletal Integrity
The purpose of this study is to find out if one year of romosozumab (Evenity®), a monthly injection given in the arm under the skin, prior to an infusion of zoledronic acid Reclast®, works to treat bone loss and prevent it from…
- Conditions
- Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
- Trial name
- RUBI (NCT05058976)
- Testing
- Romosozumab, Zoledronic acid, Calcium and Vitamin D
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Susan L. Greenspan
Osteoporosis, Postmenopausal, Osteoporosis
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
Osteoporosis remains a significant healthcare burden for the United States. Current FDA-approved osteoporosis treatments include teriparatide, abaloparatide, bisphosphonates, denosumab, and raloxifene.
- Trial name
- NCT03623633
- Testing
- denosumab, alendronate, raloxifene
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Postmenopausal Osteoporosis
Anabolic Therapy in Postmenopausal Osteoporosis
In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
- Trial name
- NCT05010590
- Testing
- Romosozumab, Denosumab
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Postmenopausal
Mechanisms of Anabolic Osteoporosis Therapy
The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.
- Trial name
- NCT05688969
- Testing
- early versus late biopsy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Postmenopausal Osteoporosis
AGE Burden and Response to Antiresorptive Therapy in Osteoporosis
Osteoporosis is a common condition that increases the risk of bone fractures. Although antiresorptive treatments such as bisphosphonates and denosumab are effective in increasing bone mineral density, some patients continue to…
- Trial name
- NCT07329543
- Volunteers
- 240 people
- Sponsor
- Bursa City Hospital
Postmenopausal Women
Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women
It is estimated that women lose around 20-25% of bone mass during the 5-10 years period of postmenopausal transition, and menopause is considered a major risk factor for osteoporotic fragility fracture.
- Trial name
- RapaLoad (NCT06789900)
- Testing
- Everolimus (Afinitor®), Football Fitness Concept
- Where
- Denmark
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Osteoporosis, Osteoporosis Postmenopausal
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a…
- Trial name
- NCT06938152
- Testing
- Romosozumab followed by Denosumab, Romosozumab and Denosumab Cycle Therapy
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- National Taiwan University Hospital